Active Ingredient(s): Enasidenib
FDA Approved: * August 1, 2017
Pharm Company: * CELGENE CORP
Category: Cancer

Enasidenib (INN; trade name Idhifa) is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test.[1] It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[2... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Idhifa 50 mg Oral Tablet, Film Coated
NDC: 59572-705
Celgene Corporation
Idhifa 100 mg Oral Tablet, Film Coated
NDC: 59572-710
Celgene Corporation